Genzyme Corp., of Cambridge, Mass., a Sanofi SA unit, said, following discussions with the FDA, the company plans to resubmit in the second quarter its supplemental biologics license application seeking to market Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.